Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Patients with Chronic Kidney Disease
ChiCTR2400083690Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin in chronic kidney disease (CKD), nephrosis, nephritic syndrome and 1 more (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Plasma dapagliflozin concentration at 12 hours. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)nephrosisnephritic syndromeglomerulopathy
Beyond the preview
Go deeper on ChiCTR2400083690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083690.